Pacific Biosciences of California, Inc. Stock
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Market Closed -
Nasdaq
08:00:00 20/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 1.760 USD | -3.83% |
|
-10.66% | -5.88% |
| 10/11 | UBS Adjusts Price Target on Pacific Biosciences of California to $2.70 From $3.05, Maintains Neutral Rating | MT |
| 05/11 | Pacific Biosciences of California, Inc., Q3 2026 Earnings Call, Nov 04, 2026 |
| Market Cap | 551M 502M 465M 420M 788M 51.44B 825M 5.61B 2.23B 27.8B 2.07B 2.02B 88.05B | P/E 2026 * |
-4.22x | P/E 2027 * | -3.89x |
|---|---|---|---|---|---|
| Enterprise Value | 1.02B 926M 857M 775M 1.45B 94.91B 1.52B 10.36B 4.11B 51.29B 3.81B 3.73B 162B | EV / Sales 2026 * |
6.45x | EV / Sales 2027 * | 6x |
| Free-Float |
91.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
| PACB | Real-time | ||
| P09 | Real-time | ||
| P09 | Real-time | ||
| P09 | Delayed | ||
| PACB * | End-of-day quote | ||
| P09 | Delayed | ||
| P09 | Delayed |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | -3.83% | ||
| 1 week | -10.66% | ||
| Current month | -32.44% | ||
| 1 month | -4.35% | ||
| 3 months | +38.58% | ||
| 6 months | +53.04% | ||
| Current year | -5.88% |
| 1 week | 1.71 | 2.02 | |
| 1 month | 1.71 | 3.06 | |
| Current year | 1.07 | 3.44 | |
| 1 year | 1.07 | 3.44 | |
| 3 years | 0.85 | 10.65 | |
| 5 years | 0.85 | 26.34 | |
| 10 years | 0.85 | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 05/08/2026 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2012 |
Todd Friedman
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 01/01/2004 |
Randy Livingston
BRD | Director/Board Member | 72 | 01/01/2009 |
Marshall Mohr
BRD | Director/Board Member | 69 | 18/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/10/26 | Exercice | Chief Financial Officer | 1,661,815 | 0.5346% | ||
| 17/8/26 | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 10/8/26 | Free | Chief Executive Officer | 2,457,018 | 0.7911% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.83% | -10.66% | 0.00% | -79.05% | 551M | ||
| -0.58% | -1.53% | +20.04% | +47.67% | 255B | ||
| -0.45% | -1.98% | +2.32% | +9.52% | 160B | ||
| -3.26% | -7.42% | -27.88% | +33.40% | 141B | ||
| -1.49% | -2.74% | -55.68% | -20.89% | 62.31B | ||
| -1.28% | -1.81% | +20.76% | +55.28% | 59.73B | ||
| -0.49% | -0.71% | +5.69% | -12.72% | 53.49B | ||
| -1.12% | +1.35% | +21.43% | +54.96% | 49.43B | ||
| -2.06% | -1.24% | +21.32% | +74.31% | 44.87B | ||
| -5.15% | -13.06% | -3.69% | +48.93% | 42.57B | ||
| Average | -1.44% | -4.04% | +0.43% | +21.14% | 87B | |
| Weighted average by Cap. | -0.57% | -3.61% | +1.70% | +31.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 157M 143M 133M 120M 225M 14.71B 236M 1.61B 637M 7.95B 591M 578M 25.18B | 178M 162M 150M 136M 255M 16.63B 267M 1.82B 720M 8.99B 668M 654M 28.47B |
| Net income | -130M -119M -110M -99.36M -186M -12.16B -195M -1.33B -527M -6.57B -489M -478M -20.82B | -144M -131M -121M -110M -206M -13.44B -216M -1.47B -582M -7.26B -540M -529M -23.01B |
| Net Debt | 466M 424M 393M 355M 666M 43.48B 697M 4.75B 1.88B 23.49B 1.75B 1.71B 74.42B | 518M 472M 437M 395M 742M 48.41B 776M 5.28B 2.1B 26.16B 1.94B 1.9B 82.86B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/11/26 | USD 1.760 | -3.83% | 20,002,001 |
| 18/11/26 | USD 1.830 | +0.55% | 15,315,685 |
| 17/11/26 | USD 1.820 | -1.09% | 13,344,810 |
| 16/11/26 | USD 1.840 | -6.12% | 14,412,378 |
| 13/11/26 | USD 1.960 | -0.51% | 7,020,622 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions
















